These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32532805)

  • 1. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase.
    DiNicolantonio JJ; McCarty M
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19.
    Bautista-Vargas M; Bonilla-Abadía F; Cañas CA
    J Thromb Thrombolysis; 2020 Oct; 50(3):479-483. PubMed ID: 32519164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 update: Covid-19-associated coagulopathy.
    Becker RC
    J Thromb Thrombolysis; 2020 Jul; 50(1):54-67. PubMed ID: 32415579
    [No Abstract]   [Full Text] [Related]  

  • 4. Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.
    Nauka PC; Oran E; Chekuri S
    Thromb Res; 2020 Aug; 192():27-28. PubMed ID: 32419710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis risk associated with COVID-19 infection. A scoping review.
    Al-Ani F; Chehade S; Lazo-Langner A
    Thromb Res; 2020 Aug; 192():152-160. PubMed ID: 32485418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19.
    Busch MH; Timmermans SAMEG; Nagy M; Visser M; Huckriede J; Aendekerk JP; de Vries F; Potjewijd J; Jallah B; Ysermans R; Oude Lashof AML; Breedveld PH; van de Poll MCG; van de Horst ICC; van Bussel BCT; Theunissen ROMFIH; Spronk HMH; Damoiseaux JGMC; Ten Cate H; Nicolaes GAF; Reutelingsperger CP; van Paassen P
    Circulation; 2020 Nov; 142(18):1787-1790. PubMed ID: 32946302
    [No Abstract]   [Full Text] [Related]  

  • 7. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
    Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
    Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2020 - Year of COVID-19.
    Lillicrap D; Morrissey JH
    J Thromb Haemost; 2020 Sep; 18(9):2081. PubMed ID: 32881334
    [No Abstract]   [Full Text] [Related]  

  • 9. How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report.
    Zanon E; Pasca S; Campello E; Spiezia L; Vettor R; Simioni P
    J Thromb Thrombolysis; 2020 Nov; 50(4):795-798. PubMed ID: 32676882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the COVID-19 pandemic on therapeutic choices in thrombosis-hemostasis.
    Hermans C; Lambert C
    J Thromb Haemost; 2020 Jul; 18(7):1794-1795. PubMed ID: 32294321
    [No Abstract]   [Full Text] [Related]  

  • 11. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.
    Zhang Y; Cao W; Jiang W; Xiao M; Li Y; Tang N; Liu Z; Yan X; Zhao Y; Li T; Zhu T
    J Thromb Thrombolysis; 2020 Oct; 50(3):580-586. PubMed ID: 32648093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemorrhagic stroke and anticoagulation in COVID-19.
    Dogra S; Jain R; Cao M; Bilaloglu S; Zagzag D; Hochman S; Lewis A; Melmed K; Hochman K; Horwitz L; Galetta S; Berger J
    J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104984. PubMed ID: 32689588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.
    McCarty MF; DiNicolantonio JJ
    Prog Cardiovasc Dis; 2020; 63(3):383-385. PubMed ID: 32061635
    [No Abstract]   [Full Text] [Related]  

  • 15. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 16. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
    Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
    Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between treatment with heparin and survival in patients with Covid-19.
    Ayerbe L; Risco C; Ayis S
    J Thromb Thrombolysis; 2020 Aug; 50(2):298-301. PubMed ID: 32476080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19.
    Hashemi A; Madhavan MV; Bikdeli B
    Semin Thromb Hemost; 2020 Oct; 46(7):789-795. PubMed ID: 32820478
    [No Abstract]   [Full Text] [Related]  

  • 19. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.
    Grimes JM; Grimes KV
    J Mol Cell Cardiol; 2020 Jul; 144():63-65. PubMed ID: 32422320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
    Whyte CS; Morrow GB; Mitchell JL; Chowdary P; Mutch NJ
    J Thromb Haemost; 2020 Jul; 18(7):1548-1555. PubMed ID: 32329246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.